INGELHEIM, Germany (ots-PRNewswire) - One-year results of HIVNET 012, a trial conducted in Uganda by the National Institute of Allergy and Infectious Diseases (NIAID) HIV Prevention Trials Network (HIVNET), confirm preliminary findings that VIRAMUNE(R) (nevirapine) effectively reduced HIV transmission from ...
DURBAN, South Africa (ots-PRNewswire) - Findings from the Atlantic study indicate that VIRAMUNE + two nucleoside analogues has shown comparable efficacy to a protease inhibitor + two nucleoside analogues. The multi-centre, international Atlantic study is the first head-to-head comparison trial of agents in the ...
Durban, South Africa (ots-PRNewswire) - Study results demonstrating the significant potency of VIRAMUNE(R) (nevirapine, NVP) were presented today at the 13th International AIDS Conference in Durban, South Africa. Findings show VIRAMUNE-based treatment combinations suppressed HIV in the blood for up to one year in patients with advanced HIV disease and high baseline ...
Durban, South Africa (ots-PRNewswire) - Results demonstrating that VIRAMUNE(R) (nevirapine) is well tolerated and effective in the prevention of mother-to-child transmission (MTCT) of HIV were presented today at the 13th International AIDS Conference. While VIRAMUNE is not currently indicated for the prevention ...
Ingelheim, Germany (ots-PRNewswire) - Boehringer Ingelheim announced today that VIRAMUNE(R) will be offered free of charge for a period of five years for the prevention of mother-to-child transmission (MTCT) of HIV-1 in developing economies. This initiative is part of Boehringer Ingelheim's commitment to the ...
Ingelheim, Germany (ots-PRNewswire) - Boehringer Ingelheim announced today that, as one of five leading pharmaceutical companies, it is joining a new initiative with United Nations organisations to explore ways to accelerate and improve the provision of HIV/AIDS-related care and treatment in developing ...
Ingelheim (ots) - Boehringer Ingelheim weist Kritik an der Wirksamkeit des Schmerzmittels Thomapyrin" mit allem Nachdruck zurück. Bei der Vorstellung des "Handbuchs Medikamente" der Stiftung Warentest am Mittwoch in Berlin waren entsprechende Behauptungen aufgestellt worden. Bei Thomapyrin handelt es ...
TAORMINA, Italy (ots-PRNewswire) - More than 750 European physicians convened here to discuss results of important clinical trials confirming the efficacy of the anti-HIV drug VIRAMUNE(R) (nevirapine) for the treatment of HIV-infected patients. Studies relating to adult and paediatric HIV treatment, as well ...
Ingelheim (ots) - In den USA wurde die Zulassung der Wirkstoffkombination aus Acetylsalicylsäure, Paracetamol und Coffein für alle Formen der Migräne erweitert. Das Kombinationsschmerzmittel Excedrin Migraine, das in seiner Zusammensetzung den Thomapyrin(r) Schmerztabletten entspricht, ist somit als einziges rezeptfreies Schmerzmittel für die Behandlung der ...
INGELHEIM, Germany (ots-PRNewswire) - Boehringer Ingelheim and Pharmacia & Upjohn (NYSE: PNU) announced today that Boehringer Ingelheim has acquired worldwide rights for Pharmacia & Upjohn's investigational protease inhibitor, tipranavir. Under the agreement, Boehringer Ingelheim will have exclusive commercial rights to tipranavir in all markets worldwide. ...
Ingelheim, Germany (ots-PRNewswire) - The Journal of the American Medical Association (JAMA) today published HIV/AIDS treatment guidelines updated by the International AIDS Society's (IAS) USA Panel on antiretroviral therapy use in adult HIV-1 infection. The updated guidelines reflect the increasingly important ...
